Etavopivat, an oral activator of red blood cell pyruvate kinase, showed promise in reducing vaso-occlusive crises and improving hemoglobin levels in patients with sickle cell disease. Results from the HIBISCUS trial revealed a decrease in annualized vaso-occlusive crisis rates, an increase in hemoglobin levels, reduced fatigue, and improved hemolysis markers with etavopivat compared to placebo. The drug may serve as a second-line therapy to hydroxyurea or a first-line treatment for those unable to tolerate hydroxyurea. However, further studies are needed to confirm its efficacy and safety before it can be widely adopted as a treatment option.
Source link
Etavopivat could offer ‘great benefit’ in sickle cell disease
